Breast cancer update from ASCO 2025 скачать в хорошем качестве

Breast cancer update from ASCO 2025

Dr Paolo Tarantino joined COR2ED direct from ASCO 2025 to report on new breast cancer data presented at the meeting. He reviews data from the SERENA-6, DESTINY-Breast09 and VERITAC-2 studies and gives his insights into how these might impact clinical practice. Studies mentioned in this video: SERENA-6: Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial. Turner N, et al. Abstract LBA4, ASCO 2025 ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in previously untreated PD-L1–positive advanced triple-negative breast cancer: Primary results from the randomised Phase 3 ASCENT-04/KEYNOTE-D19 study. Tolaney S, et al. Abstract LBA109, ASCO 2025 DESTINY-Breast09: Trastuzumab deruxtecan + pertuzumab vs taxane + trastuzumab + pertuzumab for first-line treatment of patients with HER2+ advanced/metastatic breast cancer: Interim results from DESTINY-Breast09. Tolaney S, et al. Abstract LBA1008, ASCO 2025 Get more updates from ASCO 2025 in GU, GI, ovarian and lung cancer on our website: Highlights from ASCO 2025 | COR2ED Follow BREAST CONNECT on social media: X - https://x.com/BreastCaConnect LinkedIn -   / breastcancerconnect   Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. This video was developed by https://cor2ed.com/ Published June 2025